Biosynthesis of Peptide Hormones Derived from Precursor Sequences
Authors: Eggelkraut-Gottanka, R. v.; Beck-Sickinger, A. G.
Source: Current Medicinal Chemistry, Volume 11, Number 20, October 2004 , pp. 2651-2665(15)
Publisher: Bentham Science Publishers
Abstract:The release of hormones is subject to a complex and finely tuned regulation system. The biosynthesis plays a key role by specifically converting the prohormone precursor into its biological active product(s). A family of mammalian proteases could be identified to be responsible for the endoproteolytic processing. These subtilisin / kexin-like prohormone convertases (PC) recognize their substrates at single or pairs of basic residues with a high substrate specificity. The so far known seven members include PC1 / 3, PC2, furin / PACE, PACE4, PC4, PC5 / 6 and PC7 / SPC7 / LPC / PC8. PC1 / 3 and PC2 are the most important enzymes for the processing of prohormones, whereas furin is the only one that causes lethality in knock-out models. Tissuespecific co-localization of the prohormone and the PC as well as distinct characteristics of both, like the secondary structures, determine the possible conversion processes. Identification of such determinants implies a great potential for the development of novel drug targets. To obtain sufficient amounts for the in vitro characterization of prohormones, chemical and recombinant synthesis methods have been developed. Application of expressed protein ligation lead to the semisynthesis of the first chemically modified analogs of a full-length proneurohormone (pro-neuropeptide Y). Structural analyses mainly on peptides of the prooxytocin / neurophysin system and on prosomatostatin highlighted the importance of flexible turn or loop structures adjacent to the cleavage site for the specific substrate-enzyme active site interaction. Prohormones and their processing show multiple functions. Therapeutic application including PC inhibitors is very promising for the treatment of disorders like cancer.
Document Type: Review Article
Affiliations: Institute of Biochemistry, University of Leipzig, Talstrasse 33, Bruderstr. 34, D-04103 Leipzig, Germany.
Publication date: October 1, 2004
- Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of the current topics in medicinal chemistry. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.